Last reviewed · How we verify
LIQ861 Inhaled Treprostinil
LIQ861 is an inhaled formulation of treprostinil, a prostacyclin analog that vasodilates pulmonary and systemic blood vessels by activating prostacyclin receptors.
LIQ861 is an inhaled formulation of treprostinil, a prostacyclin analog that vasodilates pulmonary and systemic blood vessels by activating prostacyclin receptors. Used for Pulmonary arterial hypertension (PAH).
At a glance
| Generic name | LIQ861 Inhaled Treprostinil |
|---|---|
| Also known as | Inhaled treprostinil, Inhaled prostacyclin, inhaled treprostinil, inhaled prostacyclin |
| Sponsor | Liquidia Technologies, Inc. |
| Drug class | Prostacyclin analog |
| Target | Prostacyclin receptor (IP receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular / Pulmonary Hypertension |
| Phase | Phase 3 |
Mechanism of action
Treprostinil mimics the action of prostacyclin, a naturally occurring eicosanoid that promotes vasodilation and inhibits platelet aggregation. By binding to prostacyclin receptors on vascular smooth muscle cells, it reduces pulmonary vascular resistance and improves blood flow. The inhaled delivery via Liquidia's proprietary LIQ technology allows direct lung deposition with potentially improved tolerability compared to systemic routes.
Approved indications
- Pulmonary arterial hypertension (PAH)
Common side effects
- Cough
- Headache
- Throat irritation
- Flushing
- Jaw pain
Key clinical trials
- An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
- Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil (PHASE3)
- Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil (PHASE3)
- Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LIQ861 Inhaled Treprostinil CI brief — competitive landscape report
- LIQ861 Inhaled Treprostinil updates RSS · CI watch RSS
- Liquidia Technologies, Inc. portfolio CI